Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT

Full Text:

Abstract

the concept of the relations between public health and national economy has appeared long time ago, but the development of quantitative methods started only in the middle of the XXth century. Until now there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment of social and economic burden of disease) is one of the most widely used. Our objective was to analyze the methodologic characteristics of researches on the cost of illness in Russia for the development of the standard methodology on evaluation of the social and economic burden related to cancers to be used further for the health technology assessment. Materials and methods. Based on the results of studying foreign and national guidelines and publications devoted to the methodological issues of the cost of illness methods, we worked out the criteria list for analysis of the methodological characteristics of this type of research. Further the developed criteria list was used to study the publications on the results of cost of illness studies in Russia. Results. In total we have analyzed 6 publications on cost of illness related to cancers and 10 publications on assessement of burden related to other diseases. The analysis was considerably hampered by the insufficient description of used methods in the majority of publications. Nethertheless we have discovered major discrepancies in the choice of methods and approaches to the assessment of the disease burden, which makes impossible comparison or use of their results for the health technology assessment. Conclusions. The undertaken analysis highlightened the need for development of standardised methods as well as standardised reporting, which would allow use of research results for health technology assessment and decision making on the financing and health care management. 

About the Authors

V. I. Ignatyeva
The Russian Presedential Academy of National Economy and Public Administration; The State Education Institution of Higher Professional Training The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation
Russian Federation


M. V. Avxentyeva
The Russian Presedential Academy of National Economy and Public Administration; The State Education Institution of Higher Professional Training The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation
Russian Federation


References

1. Bazin I.S. i dr. Meditsinskie tekhnologii. Otsenka i vybor. 2010; 2: 22-27.

2. Gasymly D.D., Tonkonogov A.S. Medical and demographic losses due to renal cell carcinoma, in the Krasnoyarsk Territory. Young organizer of public health: a collection of scientific articles of students and young scientists dedicated to the memory of Professor. VK Sologub / holes. Ed. IP Artukhov [Mediko-demograficheskie poteri, obuslovlennye poc hechno-kletochnym rakom, v Krasnoyarskom krae. Molodoi organizator zdravookhraneniya: sbornik nauchnykh statei studentov i molodykh uchenykh, posvyashchennyi pamyati prof. V.K. Sologuba / otv. red. I.P. Artyukhov]. Krasnoyarsk. 2013; 448 s.

3. Efimova N.V., Nikiforova V.A. Vestnik Sankt-Peterburgskogo Universiteta. 2008; 11 (4): 196-201.

4. Ivakhnenko O.I., Avksent'eva M.V., Maksimova L.V. Otsenka i vybo r . 2013; 1: 29-35.

5. Kamalova F.M. i dr. Gorodskoe zdravookhranenie. 2008; 5: 50-51.

6. Clinical and economic analysis. 3rd edition, complemented with applications. Ed. PA Vorobyov. Moscow [Kliniko-ekonomicheskii analiz. Izdanie 3-e, dopolnennoe, s prilozheniyami]. Pod red. P.A. Vorob'eva. M. 2008b; 778 s.

7. Kolbin A.S . i dr. Klinicheskaya farmakologiya i terapiya. 2010; 19 (4): 17-22.

8. Kontsevaya A.V. i dr. Ratsional'naya farmakoterapiya v kardiologii. 2011; 7 (2): 158-166.

9. Krysanov I.S., Yagudina R.I., Moiseeva T.N. Vestnik Roszdravnadzora. 2008; 4: 34-39.

10. Kulikov A.Yu., Dedyurina Yu.M. Farmakoekonomika. Sovremennaya farmakoekonomi ka i farmakoepidemiologiya. 2011; 4 (1): 24-33.

11. Lyubov E.B. i dr. Sotsial'naya i klinicheskaya psikhiatriya. 2012; 22 (3): 36- 42.

12. Malievskii V.A. Nauchno-prakticheskaya revmatologiya. 2006; 2: 96b-96.

13. Omel'yanovskii V.V., Avksent'eva M.V., Derka ch E.V., Sveshnikova N.D. Pediatricheskaya farmakologiya. 2011; 8 (3): 6-12.

14. Omel'yanovskii V.V., Avksent'eva M.V., Derkach E.V., Sveshnikova N.D. Otsenka i vybor. 2011; 1: 42-50.

15. Poddubnaya I.V., Aksel' E.M., Kipriyanova N.S. Sibirskii onkologicheskii zhurnal. 2007; 3 (23): 64-68.

16. Sosnovskaya E.V., Nikolaev N.A. Saratovskii nauchnomeditsinskii zhurnal. 2011; 7 (2): 418-420.

17. Socio-economic burden of asthma and chronic obstructive pulmonary d isease in the Russian Federation. Research report. Ed. VV Omel'yanovskii. Regional Charitable Foundation to promote activities in the field of health promotion «Quality of Life» [Sotsial'noekonomicheskoe bremya bronkhial'noi astmy i khronicheskoi obstruktivnoi bolezni legkikh v Rossiiskoi Federatsii. Otchet po issl edovaniyu. Pod red. V.V. Omel'yanovskogo. Regional'nyi blagotvoritel'nyi obshchestvennyi fond sodeistviya deyatel'nosti v sfere propagandy zdorovogo obraza zhizni «Ka chestvo zhizni»]. Moscow. 2010; 30 s.

18. Shapovalova M.A., Bondarev V.A., Koretskaya L.R. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh i ssledovanii. 2012; 7: 143-144.

19. Yushchuk N.D. i dr. Meditsinskie tekhnologii. Otsenka i vybor. 2012; 4: 46-51.

20. Yagudina R.I., Zinchuk I .Yu., Litvinenko M.M. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemio logiya. 2012; 1: 4-9.

21. Abegunde D.O. et al. The burden and costs of chronic diseases in low-income and middle-income countries. The Lancet. 2007; 370 (9603): 1929-1938.

22. Akobundu E., Ju J., Blatt L., Mullins C.D. Cost-of-Illness studies: a review of current methods. Pharmacoeconomics. 2006; 24 (9): 869- 90. [PubMed: 16942122].

23. Akobundu E. et al. Cost-of-Illness Studies. Pharmacoeconomics. 2006; 24 (9): 869-890.

24. Ament A., Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy. 1993; 26: 29-42.

25. American Diabetes Association et al. Economic costs of diabetes in the US in 2007. Diabetes care. 2008; 31 (3): 596-615.

26. Berger M.L. et al. Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms. International Society for Pharmacoeconomics and Outcomes Research. 2003.

27. Bloom B.S., Bruno D.J., Maman D.Y., Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decisionmaking. Pharmacoeconomics. 2001; 19 (2): 207-13.

28. Byford S., Torgerson D.J., Raftery J. Cost of illness studies. BMJ. 2000; 320 (7245): 1335.

29. Centers for disease control and prevention. Division for Heart Disease and Stroke Prevention. Five-Part Webcast on Economic Evaluation. http://www.cdc.gov/dhdsp/programs/nhdsp_program/ economic_evaluation/Module_II/Podcast_II.pdf.

30. Chisholm D. et al. Economic impact of disease and injury: counting what matters. BMJ. 2010; 340. http://www.who.int/choice/publications/Economic_impact_paperBMJ.pdf.

31. Clabaugh G., Ward M.M. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value in Health. 2008; 11 (1): 13-21. [PubMed: 18237356].

32. Collins D., Lapsley H. The social costs of drug abuse in Australia in 1988 and 1992. Commonwealth Department of Human Services and Health. 1996 Feb [online]. http://www.health.gov.au/internet/main/Publishing.nsf/Content/health-pubhlth-publicat-document-mono30-cnt.htm.

33. Drummond M.F: Methods for the economic evaluation of health care programmes. 3rd edition. Oxford. 2005.

34. Frank R.G. et al. Medicaid And Mental Health: Be Careful What You Ask For. Health Aff. January. 2003; 22 (1): 101-113.

35. Gold M.R. Siegel J.E. Russell L.B. et al. Cost-Effectiveness in Health and Medicine. New York. 1996.

36. Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2006. http://www.inahta.org/wpcontent/themes/inahta/img/AboutHTA_Guidelines_for_the_Economic_Evaluation_of_Health_Technologies.pdf.

37. Hanly P. et al. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach.Value in Health. 2012; 15 (3): 429-436.

38. Hodgson T.A., Meiners M.R. Cost of illness methodology: a guide to current practices and procedures. Milbank Memorial Fund Quarterly. 1982; 60 (3): 429-462.

39. Hodgson T.A. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics. 1994; 6 (6): 536-52.

40. Introduction and methods: assessing the environmental burden of disease at national and local levels. http://www.who.int/quantifying_ ehimpacts/publications/9241546204/en/.

41. Koopmanshap M. Cost-of-Illness Studies. Useful for Health Policy? Pharmacoeconomics. 1998; 14: 143-148.

42. Larg A., Moss J. R. Cost-of-Illness Studies. Pharmacoeconomics. 2011; 29 (8): 653-671.

43. Molinier L., Bauvin E., Combescure C., Castelli C., Rebillard X., Soulié M., Daurès J.P., Grosclaude P. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008; 11 (5): 878-885.

44. Murray C.J.L., Lopez A.D. eds. Global comparative assessments in the health sector: disease burden, expenditure and intervention packages. Geneva. 1994.

45. Rice D.P. Cost of illness studies: what is good about them? Injury Prevention. 2000; 6: 177-179.

46. Rice D.P. Cost-of-illness studies: fact or fiction? Lancet. 1994; 344: 1519-20.

47. Rice D.P. Estimating the cost of illness. Health Economic Series No 6. Washington, DC: US Government Priming Office. 1966; 947-6.

48. Rosen A.B., Cutler D.M. Challenges in building disease-based national health accounts. Medical care. 2009; 47 (7 Suppl 1): S7.

49. Segel J.E. Cost-of-illness Studies – A Primer. RTI International.http://www.ppge.ufrgs.br/giacomo/arquivos/cd%20congresso%20gramado/artigos/segel-2006.pdf.

50. Shiell A., Gerard K., Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy. 1987; 8: 317-23.

51. Suhrcke M. et al. Economic Consequences of Noncommunicable Diseases and Injuries in the Russian Federation. 2007. http://www.euro.who.int/__data/assets/pdf_file/0005/74741/E89992.pdf.

52. Suhrcke M. et al. The contribution of health to the economy in the European Union. 2005. http://ec.europa.eu/health/archive/ph_overview/documents/health_economy_en.pdf

53. Suhrcke M. Urban D. Is cardiovascular disease bad for economic growth? Venice: WHO European Office for Investment for Health and Development. 2006.

54. Tarricone R. Cost-of-illness analysis: What room in health economics? Health Policy. 2006; 77 (1): 51-63.

55. The cost of illness handbook. http://www.epa.gov/oppt/coi/.

56. Twigg J.L. The cost of illness, disability, and premature mortality to Russia's economy. Eurasian Geography and Economics. 2005; 46 (7): 495-524.

57. WHO guide to identifying the economic consequences of disease and injury. http://www.who.int/choice/publications/d_economic_impact_guide.pdf/.

58. WHO. Preventing chronic diseases: a vital investment: WHO global report. Geneva. 2005.

59. Winter Y. et al. Costs of illness in a Russian cohort of patients with Parkinson’s disease. Pharmacoeconomics. 2009; 27 (7): 571-584.


For citation:


Ignatyeva V.I., Avxentyeva M.V. THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2014;7(3):3-11. (In Russ.)

Views: 999


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)